Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025) (ODO-P8-689)

This study has been completed.
Sponsor:
Information provided by:
Aptalis Pharma
ClinicalTrials.gov Identifier:
NCT00981487
First received: September 21, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted

September 21, 2009
September 21, 2009
February 2009
March 2009   (final data collection date for primary outcome measure)
Effects of food on the pharmacokinetics of a single 24 mg dose of ondansetron administered under fed abd fasting conditions [ Time Frame: 1 dose on two separate days ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025)
Single-Dose Crossover Comparative Bioavailability Study to Assess the Effect of Food on the Pharmacokinetics of Ondansetron Modified-Release Capsules (EUR-1025) in Healthy Male and Female Volunteers

This study is to assess the effect of food on a single dose of Ondansetron when taken with a meal on an empty stomach.

The objective of this study is to assess the effect of food on the pharmacokinetics of a single 24 mg dose of Ondansetron administered as a novel modified-release capsule formulation under fed and fasting conditions.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Nausea
  • Drug: Ondansetron
    24 mg one time
    Other Name: EUR-1025
  • Drug: Ondansetron
    24 mg, on time in the am
    Other Name: EUR-1025
  • Experimental: Fed
    A single oral dose of EUR-1025 (1x24 mg) will be administered with approximately 240 ml of water in the morning. The Ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast.
    Intervention: Drug: Ondansetron
  • Experimental: Fasting
    A single oral dose of EUR-1025 (1x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
    Intervention: Drug: Ondansetron
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
March 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • male and female volunteers,
  • non or ex-smokers,
  • at least 21 years of age but not older than 55 years,
  • a body mass index targeted to be at least 18.5 and less than 30 kg/m2
  • healthy,
  • acceptable normal lab tests,
  • negative HIV, Hepatitis B & C,
  • a negative ethyl alcohol and drug screen,
  • normal 12 lead ECG, AND
  • negative HCG for females.

Exclusion Criteria:

  • no known hypersensitivity to ondansetron or any related products,
  • presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects,
  • history of significant gastrointestinal, liver or kidney disease,
  • presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric endocrine, immunologic or dermatologic disease, suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric disease, presence of significant heart disease or disorder discovered on screening ECG,
  • females who are found to have a positive serum pregnancy test at screening or are nursing,
  • females of childbearing potential who refuse to use an acceptable contraceptive regimen from the screening visit and throughout the study,
  • maintenance therapy with any drug,
  • significant history of drug dependency or alcohol abuse (> 2 units of alcohol per day, intake of excessive alcohol, acute or chronic),
  • any clinically significant illness in the previous 28 days before day 1 of the study,
  • use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, dilitiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampin), in the previous 28 days before day 1 of this study,
  • volunteers who took an Investigational Product (in another clinical trial) or donated 50 ml or more of blood in the previous 28 days before day 1 of this study,
  • poor motivation,
  • intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements or inability to cooperate adequately,
  • inability to understand and to observe the instructions of the physician,
  • donation of 500 ml or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies) in the previous 56 days before day 1 of this study,
  • positive urine screening of drugs or abuse,
  • any history of tuberculosis and/or prophylaxis for tuberculosis, OR
  • positive results to HIV, HBsAg, or anti-HCV tests.
  • no subject will be allowed to enroll in this study more than once.
Both
21 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00981487
EUR-1025
No
Ruth Thieroff-Ekerdt, M.D., Eurand Pharmaceuticals, Inc.
Aptalis Pharma
Not Provided
Principal Investigator: Eric Sicard, M.D. Algorithme Pharma Inc
Aptalis Pharma
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP